Deferred Income Tax Assets, Net of ALNYLAM PHARMACEUTICALS, INC. from 31 Dec 2023 to 30 Sep 2025

Taxonomy & unit: us-gaap: USD
Description: Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.
Summary: ALNYLAM PHARMACEUTICALS, INC. quarterly Deferred Income Tax Assets, Net in USD history and change rate from 31 Dec 2023 to 30 Sep 2025.
ALNYLAM PHARMACEUTICALS, INC. Deferred Income Tax Assets, Net for the quarter ending 30 Sep 2025 was $98,558,000.
Source SEC data: View on sec.gov

Deferred Income Tax Assets, Net, Quarterly (USD)

Deferred Income Tax Assets, Net, YoY Quarterly Change (%)

ALNYLAM PHARMACEUTICALS, INC. Quarterly Deferred Income Tax Assets, Net (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2025	$98,558,000			30 Sep 2025	10-Q	30 Oct 2025	2025	Q3
Q2 2025	$104,363,000			30 Jun 2025	10-Q	31 Jul 2025	2025	Q2
Q1 2025	$107,224,000			31 Mar 2025	10-Q	01 May 2025	2025	Q1
Q4 2024	$116,863,000	+$106,762,000	+1057%	31 Dec 2024	10-Q	30 Oct 2025	2025	Q3
Q4 2023	$10,101,000			31 Dec 2023	10-K	13 Feb 2025	2024	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.